VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

06 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

01 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

30 May 2024 16:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

15 May 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

13 May 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

08 May 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

26 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

29 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

27 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

22 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

05 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

29 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

04 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

03 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

15 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

10 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire